- To heparinize or not to heparinize: Effect on arterial blood gas measurements. [Journal Article]
- IJIndian J Crit Care Med 2014; 18(1):1-2
- Haemodialysis in patients treated with oral anticoagulant: should we heparinize? [Randomized Controlled Trial]
- NDNephrol Dial Transplant 2014; 29(4):906-13
- CONCLUSIONS: These results suggest that haemodialysis without additional anticoagulation is possible in patients with oral anticoagulation. The HeprAN membrane did not provide any additional benefit compared with a PS membrane.
- Is heparin needed for patients with an intra-aortic balloon pump? [Review]
- ICInteract Cardiovasc Thorac Surg 2012; 15(1):136-9
- We addressed the question of whether or not the currently available evidence base supports heparinization in the context of a patient requiring cardiovascular support with an intra-aortic balloon pum…
We addressed the question of whether or not the currently available evidence base supports heparinization in the context of a patient requiring cardiovascular support with an intra-aortic balloon pump (IABP). A best evidence topic was written according to a previously defined structured protocol. A literature search returned 443 papers, 3 of which were deemed relevant. Jiang et al. randomized 153 patients requiring IABP to heparin or no heparin, matched for age, sex and comorbidities. There was no significant difference in limb ischaemia; however, incidence of bleeding was significantly increased in the heparinized group (14.1 vs 2.4%). One cohort study compared two management strategies of IABP in which patients either received heparin universally or selectively with heparin only given for certain pre-defined indications. They reported increased bleeding with universal heparinization (39.2 vs 31.8%) but similar other complication rates. Another cohort study in which patients with IABP were initially treated with glycoprotein IIb/IIIa antagonists only, reported bleeding and ischaemia rates within accepted ranges for heparinized patients. The use of anticoagulation with IABP is intended to reduce the risk of thrombus, thromboembolus or limb ischaemia whilst generating an increased risk of bleeding as a side-effect. The aforementioned studies demonstrate that omitting or implementing a selective use strategy of heparinization during IABP counterpulsation can significantly decrease the incidence of bleeding without an increase in ischaemic events. One study also performed angiography prior to IABP insertion on some of their patients, selecting the less diseased side to insert the IABP. Current evidence on this topic is sparse, especially as relates to patients in the context of cardiothoracic surgery. Just one study specifically looked at surgical patients. However, the existing data suggest that it is safe to omit heparinization when using IABP counterpulsation. The decision to heparinize should be weighed in the context of other indications or contraindications rather than being an automatic response to the use of IABP.
- Preparation and characterization of chitosan-heparin composite matrices for blood contacting tissue engineering. [Journal Article]
- BMBiomed Mater 2010; 5(5):055001
- Chitosan has been widely used for biomaterial scaffolds in tissue engineering because of its good mechanical properties and cytocompatibility. However, the poor blood compatibility of chitosan has gr…
Chitosan has been widely used for biomaterial scaffolds in tissue engineering because of its good mechanical properties and cytocompatibility. However, the poor blood compatibility of chitosan has greatly limited its biomedical utilization, especially for blood contacting tissue engineering. In this study, we exploited a polymer blending procedure to heparinize the chitosan material under simple and mild conditions to improve its antithrombogenic property. By an optimized procedure, a macroscopically homogeneous chitosan-heparin (Chi-Hep) blended suspension was obtained, with which Chi-Hep composite films and porous scaffolds were fabricated. X-ray photoelectron spectroscopy and sulfur elemental analysis confirmed the successful immobilization of heparin in the composite matrices (i.e. films and porous scaffolds). Toluidine blue staining indicated that heparin was distributed homogeneously in the composite matrices. Only a small amount of heparin was released from the matrices during incubation in normal saline for 10 days. The composite matrices showed improved blood compatibility, as well as good mechanical properties and endothelial cell compatibility. These results suggest that the Chi-Hep composite matrices are promising candidates for blood contacting tissue engineering.
- [Some influence factors in determination of serum enzyme in hepatitis patients]. [Journal Article]
- ZSZhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi 2008; 22(5):385-7
- CONCLUSIONS: Different conditions and reagents will influence results. To obtain correct data, we must institute and perform standard regulation.
- CASE 5 - 2008: Epidural Hematoma: when is it safe to heparinize after the removal of an epidural catheter? [Case Reports]
- JCJ Cardiothorac Vasc Anesth 2008; 22(5):774-8
- Minimizing the incidence of heparin-induced thrombocytopenia: to heparinize or not to heparinize vascular access? [Editorial]
- PAPaediatr Anaesth 2005; 15(12):1037-40
- Safety of heparinization for cerebral aneurysm coiling soon after external ventriculostomy drain placement. [Review]
- NNeurosurgery 2005; 57(5):845-9; discussion 845-9
- CONCLUSIONS: Heparinization for cerebral aneurysm coiling can be safely performed even after EVD placement within 24 hours, particularly if the activated prothrombin time is kept strictly controlled.
- Modified Blalock-Taussig shunts: to heparinize or not to heparinize? [Journal Article]
- CJCan J Cardiol 1996; 12(7):645-7
- CONCLUSIONS: Avoidance of heparin after an MBTS procedure is a safe practice and may reduce bleeding problems and the incidence of significant seromas surrounding the graft. Postoperative shunt thrombosis is more likely related to intraoperative technical difficulty or extremely small pulmonary artery size.
New Search Next
- Hageman factor deficiency presentation and implications for management. [Journal Article]
- CMConn Med 1992; 56(9):469-71
- One of the more fascinating aspects of patient management arises when dealing with coagulation disorders. Factor XII deficiency, first described by Ratnoff in 1968, is one such coagulation disorder w…
One of the more fascinating aspects of patient management arises when dealing with coagulation disorders. Factor XII deficiency, first described by Ratnoff in 1968, is one such coagulation disorder which provides some interesting challenges in management. Factor XII deficiency has been shown to be an inherited autosomal recessive disorder. The presence of Hageman factor abnormality trait can be clinically suspected in a patient with a prolonged activated partial thromboplastin time (APTT), normal prothrombin time (PT), normal bleeding time, and no clinical history of bleeding. Once suspected, the deficiency can be confirmed by normalization of partial thromboplastin time (PTT) with normal aged plasma and by factor assay. The importance of understanding the mechanism of factor XII deficiency has clinical significance when attempts are made to heparinize individuals who have this deficiency. Three methods can be used to monitor therapy: the chromogenic heparin assay, the citrated thrombin time, and the recalcified thrombin time. Two cases are presented.